Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A small molecule experimental drug with a molecular formula of C21H18F2N2O and a molecular weight of approximately 352.38 g/mol. It is classified as a stilbene derivative and has been investigated for its potential activity against dipeptidyl peptidase 4 (DPP-IV), but there is no evidence of clinical development or approval for any indication[6]. The compound is not currently marketed or approved in any country.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide.